{"id":17766,"date":"2020-01-31T14:21:48","date_gmt":"2020-01-31T13:21:48","guid":{"rendered":"https:\/\/www.satt.fr\/ft120\/"},"modified":"2020-01-31T14:21:48","modified_gmt":"2020-01-31T13:21:48","slug":"ft120","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/ft120\/","title":{"rendered":"French Tech 120 : 6 start-ups accompagn\u00e9es par les SATT parmi les entreprises s\u00e9lectionn\u00e9es"},"content":{"rendered":"<div id=\"pl-17766\"  class=\"panel-layout\" ><div id=\"pg-17766-0\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-17766-0-0\"  class=\"panel-grid-cell\" ><div id=\"panel-17766-0-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><strong>La premi\u00e8re promotion du French Tech 120 est enfin compl\u00e8te. 83 entreprises viennent rejoindre les 40 jeunes pousses du Next 40, dont\u00a06 start-up accompagn\u00e9es : Acticor Biotech, Dynacure, Inotrem, ImCheck Therapeutics, Keranova, Treefrog Therapeutics.<\/strong><\/p>\n<p>Lanc\u00e9 en septembre 2019 par le Pr\u00e9sident de la R\u00e9publique et le Premier Ministre, le programme <a href=\"https:\/\/lafrenchtech.com\/fr\/la-france-aide-les-startups\/french-tech-120-2\/\">French Tech 120<\/a> illustre la volont\u00e9 du gouvernement fran\u00e7ais de devenir le meilleur des soutiens possibles pour l\u2019\u00e9cosyst\u00e8me de la French Tech.<\/p>\n<p>Ce programme d\u00e9di\u00e9 aux startups en phase d\u2019hyper-croissance offre un accompagnement sans pr\u00e9c\u00e9dent \u00e0 123 entreprises en fort d\u00e9veloppement. En mettant en commun les comp\u00e9tences de nombreuses agences gouvernementales, minist\u00e8res et services publics, le dispositif French Tech 120 vise \u00e0 stimuler la croissance et cr\u00e9er des opportunit\u00e9s en France, dans le sillage du succ\u00e8s de ces startups \u00e0 l\u2019international.<\/p>\n<p>\u00catre membre de la French Tech 120 c\u2019est\u00a0:<\/p>\n<ul>\n<li>\u00catre reconnu comme une start-up en capacit\u00e9 de devenir un leader technologique de rang mondial<\/li>\n<li>Acc\u00e9der \u00e0 un r\u00e9seau de 120 start-ups, pr\u00e9sentes partout en France, et b\u00e9n\u00e9ficier de retours d\u2019exp\u00e9riences partag\u00e9es<\/li>\n<li>Participer \u00e0 la reconnaissance de l\u2019\u00e9cosyst\u00e8me French Tech, en France et \u00e0 l\u2019international<\/li>\n<li>S\u2019engager sur les valeurs de l\u2019\u00e9cosyst\u00e8me<\/li>\n<li>B\u00e9n\u00e9ficier d\u2019un accompagnement de l\u2019\u00c9tat con\u00e7u pour des futurs leaders technologiques<\/li>\n<\/ul>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-17744\" src=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/RS_Start-up_titre_270120-2048x1365-300x200.png\" alt=\"\" width=\"600\" height=\"400\" srcset=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/RS_Start-up_titre_270120-2048x1365-300x200.png 300w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/RS_Start-up_titre_270120-2048x1365-150x100.png 150w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/RS_Start-up_titre_270120-2048x1365-768x512.png 768w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/RS_Start-up_titre_270120-2048x1365-1024x683.png 1024w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/RS_Start-up_titre_270120-2048x1365-500x333.png 500w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/RS_Start-up_titre_270120-2048x1365-600x400.png 600w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/RS_Start-up_titre_270120-2048x1365-272x182.png 272w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/RS_Start-up_titre_270120-2048x1365.png 2048w\" sizes=\"auto, (max-width: 600px) 100vw, 600px\" \/><\/p>\n<p><strong>Les 6 start-up du FT120 accompagn\u00e9es par les SATT :<\/strong><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-17766-1\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-17766-1-0\"  class=\"panel-grid-cell\" ><div id=\"panel-17766-1-0-0\" class=\"so-panel widget widget_media_image panel-first-child panel-last-child\" data-index=\"1\" ><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"68\" src=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/acticor_logo_large-150x68.png\" class=\"image wp-image-17694  attachment-thumbnail size-thumbnail\" alt=\"\" style=\"max-width: 100%; height: auto;\" srcset=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/acticor_logo_large-150x68.png 150w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/acticor_logo_large-300x135.png 300w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/acticor_logo_large-768x347.png 768w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/acticor_logo_large-1024x462.png 1024w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/acticor_logo_large-500x226.png 500w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/acticor_logo_large-600x271.png 600w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/acticor_logo_large-200x90.png 200w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/acticor_logo_large.png 2000w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/div><\/div><div id=\"pgc-17766-1-1\"  class=\"panel-grid-cell\" ><div id=\"panel-17766-1-1-0\" class=\"so-panel widget widget_text panel-first-child panel-last-child\" data-index=\"2\" >\t\t\t<div class=\"textwidget\"><p><strong>Acticor Biotech<\/strong> est une soci\u00e9t\u00e9 de biotechnologie en phase clinique impliqu\u00e9e dans la phase aigu\u00eb des maladies thrombotiques, y compris les accidents vasculaires c\u00e9r\u00e9braux isch\u00e9miques aigus.<\/p>\n<p>Acticor Biotech et la <strong>SATT Ouest Valorisation<\/strong> ont conclu un accord de sous-licence octroyant \u00e0 la soci\u00e9t\u00e9 les droits mondiaux de d\u00e9velopper et d\u2019exploiter le biomarqueur dans l\u2019AVC. Acticor Biotech a acquis 100% des actions d\u2019AVCare, une start-up sp\u00e9cialis\u00e9e dans le diagnostic. AVCare a \u00e9t\u00e9 cr\u00e9\u00e9e par le Pr. Serge Timsit et Jean-Marc Herbert et est financ\u00e9e par la SATT Ouest Valorisation et GO Capital.<\/p>\n<p><a href=\"https:\/\/acticor-biotech.com\/\">acticor-biotech.com<\/a><\/p>\n<\/div>\n\t\t<\/div><\/div><\/div><div id=\"pg-17766-2\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-17766-2-0\"  class=\"panel-grid-cell\" ><div id=\"panel-17766-2-0-0\" class=\"so-panel widget widget_media_image panel-first-child panel-last-child\" data-index=\"3\" ><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"40\" src=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/dynacure_logo-150x40.png\" class=\"image wp-image-17696  attachment-thumbnail size-thumbnail\" alt=\"\" style=\"max-width: 100%; height: auto;\" srcset=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/dynacure_logo-150x40.png 150w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/dynacure_logo-300x80.png 300w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/dynacure_logo-200x53.png 200w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/dynacure_logo.png 488w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/div><\/div><div id=\"pgc-17766-2-1\"  class=\"panel-grid-cell\" ><div id=\"panel-17766-2-1-0\" class=\"so-panel widget widget_text panel-first-child panel-last-child\" data-index=\"4\" >\t\t\t<div class=\"textwidget\"><p><strong>Dynacure<\/strong> d\u00e9veloppe de nouveaux traitements pour les patients atteints de maladies orphelines graves.<\/p>\n<p>Spin-off de l&#8217;Institut de g\u00e9n\u00e9tique et de biologie mol\u00e9culaire et cellulaire (IGBMC) de Strasbourg. Elle s\u2019appuie sur les r\u00e9sultats des travaux du Dr. Jocelyn Laporte, qui ont b\u00e9n\u00e9fici\u00e9 d\u2019un investissement en maturation de<strong> Conectus<\/strong> de pr\u00e8s de 450K\u20ac.<\/p>\n<p><a href=\"http:\/\/www.dynacure.com\">www.dynacure.com<\/a><\/p>\n<\/div>\n\t\t<\/div><\/div><\/div><div id=\"pg-17766-3\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-17766-3-0\"  class=\"panel-grid-cell\" ><div id=\"panel-17766-3-0-0\" class=\"so-panel widget widget_media_image panel-first-child panel-last-child\" data-index=\"5\" ><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"42\" src=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/INOTREM_Logo-Gris-150x42.png\" class=\"image wp-image-17698  attachment-thumbnail size-thumbnail\" alt=\"\" style=\"max-width: 100%; height: auto;\" srcset=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/INOTREM_Logo-Gris-150x42.png 150w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/INOTREM_Logo-Gris-300x83.png 300w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/INOTREM_Logo-Gris-768x213.png 768w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/INOTREM_Logo-Gris-500x139.png 500w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/INOTREM_Logo-Gris-600x167.png 600w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/INOTREM_Logo-Gris-200x56.png 200w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/INOTREM_Logo-Gris.png 835w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/div><\/div><div id=\"pgc-17766-3-1\"  class=\"panel-grid-cell\" ><div id=\"panel-17766-3-1-0\" class=\"so-panel widget widget_text panel-first-child panel-last-child\" data-index=\"6\" >\t\t\t<div class=\"textwidget\"><p><strong>Inotrem <\/strong>est une soci\u00e9t\u00e9 de biotechnologie sp\u00e9cialis\u00e9e dans le contr\u00f4le de la r\u00e9ponse immunitaire lors de maladies inflammatoires aig\u00fces et chroniques, telles que le choc septique.<\/p>\n<p>La soci\u00e9t\u00e9 a \u00e9t\u00e9 cr\u00e9\u00e9e sur les travaux de 2 chercheurs nanc\u00e9ens, le Pr S\u00e9bastien Gibot, et le Dr Marc Derive (UMR INSERM\/ Universit\u00e9 de Lorraine \/ CHU). <strong>SAYENS<\/strong> accompagne depuis des ann\u00e9es la soci\u00e9t\u00e9 et depuis fin 2017, SAYENS s\u2019est associ\u00e9e \u00e0 Inserm Transfert pour n\u00e9gocier les termes des licences de plusieurs familles de brevets, pour les co-proprietaires (Inserm et Universit\u00e9 de Lorraine). En septembre 2019, Inotrem a lev\u00e9 39 millions d&#8217;euros qui lui permettront d\u2019acc\u00e9l\u00e9rer ses d\u00e9veloppements cliniques en Europe et aux USA, o\u00f9 elle a obtenu le statut Fast Track de la FDA.<\/p>\n<p><a href=\"http:\/\/www.inotrem.com\/\">www.inotrem.com<\/a><\/p>\n<\/div>\n\t\t<\/div><\/div><\/div><div id=\"pg-17766-4\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-17766-4-0\"  class=\"panel-grid-cell\" ><div id=\"panel-17766-4-0-0\" class=\"so-panel widget widget_media_image panel-first-child panel-last-child\" data-index=\"7\" ><img loading=\"lazy\" decoding=\"async\" width=\"100\" height=\"134\" src=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/Imcheck-therapeutics_blue_home-112x150.png\" class=\"image wp-image-17700  attachment-100x134 size-100x134\" alt=\"\" style=\"max-width: 100%; height: auto;\" srcset=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/Imcheck-therapeutics_blue_home-112x150.png 112w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/Imcheck-therapeutics_blue_home-75x100.png 75w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/Imcheck-therapeutics_blue_home.png 187w\" sizes=\"auto, (max-width: 100px) 100vw, 100px\" \/><\/div><\/div><div id=\"pgc-17766-4-1\"  class=\"panel-grid-cell\" ><div id=\"panel-17766-4-1-0\" class=\"so-panel widget widget_text panel-first-child panel-last-child\" data-index=\"8\" >\t\t\t<div class=\"textwidget\"><p><strong>ImCheck Therapeutics<\/strong> est une biotech marseillaise sp\u00e9cialis\u00e9e dans l&#8217;immunoth\u00e9rapie des cancers et des maladies du syst\u00e8me immunitaire, spin-off du Centre de Recherche en Canc\u00e9rologie de Marseille, associant l\u2019Institut Paoli-Calmettes, Aix-Marseille Universit\u00e9, l\u2019Inserm et le CNRS.<\/p>\n<p>Issue des travaux de recherche en immunologie fondateurs du Professeur Daniel OLIVE de l\u2019Institut Paoli Calmettes (Aix-Marseille Universit\u00e9) et du Centre de Recherche en Canc\u00e9rologie de Marseille. Sous-licence \u00e0 la <strong>SATT Sud-Est<\/strong> ; deux contrats de co-maturation sont en court.<\/p>\n<p><a href=\"http:\/\/www.imchecktherapeutics.com\/\">www.imchecktherapeutics.com<\/a><\/p>\n<\/div>\n\t\t<\/div><\/div><\/div><div id=\"pg-17766-5\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-17766-5-0\"  class=\"panel-grid-cell\" ><div id=\"panel-17766-5-0-0\" class=\"so-panel widget widget_media_image panel-first-child panel-last-child\" data-index=\"9\" ><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"67\" src=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/unnamed-150x67.png\" class=\"image wp-image-17702  attachment-thumbnail size-thumbnail\" alt=\"\" style=\"max-width: 100%; height: auto;\" srcset=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/unnamed-150x67.png 150w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/unnamed-300x134.png 300w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/unnamed-200x89.png 200w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/unnamed.png 479w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/div><\/div><div id=\"pgc-17766-5-1\"  class=\"panel-grid-cell\" ><div id=\"panel-17766-5-1-0\" class=\"so-panel widget widget_text panel-first-child panel-last-child\" data-index=\"10\" >\t\t\t<div class=\"textwidget\"><p><strong>KERANOVA<\/strong> est une start-up \u00e9voluant dans le domaine des technologies m\u00e9dicales innovantes qui con\u00e7oit et d\u00e9veloppe des \u00e9quipements chirurgicaux de bloc op\u00e9ratoire destin\u00e9s \u00e0 diff\u00e9rentes indications ophtalmologiques du segment ant\u00e9rieur de l\u2019\u0153il.<\/p>\n<p>Issue des laboratoires st\u00e9phanois de l\u2019Universit\u00e9 Jean Monnet sous l\u2019impulsion des Professeurs Philippe Gain et Gilles Thuret. Keranova a sign\u00e9 une licence d\u2019exploitation exclusive avec <strong>PULSALYS<\/strong>.<\/p>\n<p><a href=\"http:\/\/www.keranova.fr\/\">www.keranova.fr<\/a><\/p>\n<\/div>\n\t\t<\/div><\/div><\/div><div id=\"pg-17766-6\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-17766-6-0\"  class=\"panel-grid-cell\" ><div id=\"panel-17766-6-0-0\" class=\"so-panel widget widget_media_image panel-first-child panel-last-child\" data-index=\"11\" ><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"48\" src=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/logo_treefrog_RVB-150x48.png\" class=\"image wp-image-17704  attachment-thumbnail size-thumbnail\" alt=\"\" style=\"max-width: 100%; height: auto;\" srcset=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/logo_treefrog_RVB-150x48.png 150w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/logo_treefrog_RVB-300x97.png 300w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/logo_treefrog_RVB-768x248.png 768w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/logo_treefrog_RVB-1024x330.png 1024w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/logo_treefrog_RVB-500x161.png 500w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/logo_treefrog_RVB-600x193.png 600w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/logo_treefrog_RVB-200x64.png 200w, https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/logo_treefrog_RVB.png 1086w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/div><\/div><div id=\"pgc-17766-6-1\"  class=\"panel-grid-cell\" ><div id=\"panel-17766-6-1-0\" class=\"so-panel widget widget_text panel-first-child panel-last-child\" data-index=\"12\" >\t\t\t<div class=\"textwidget\"><p><strong>TreeFrog Therapeutics<\/strong> offre \u00e0 l\u2019industrie pharmaceutique une solution pour produire des cellules souches en masse en r\u00e9duisant les co\u00fbts et avec un standard de qualit\u00e9 in\u00e9dit<\/p>\n<p>Port\u00e9 par Maxime Feyeux et Kevin Alessandri, du Laboratoire Photonique, Num\u00e9rique et Nanosciences \u2013 LP2N (universit\u00e9 de Bordeaux, CNRS, Institut d\u2019Optique). Soutenue par Aquitaine Science Transfert dans le cadre d\u2019un programme de maturation avec un investissement de 1,2M\u20ac. TreeFrog Therapeutics a sign\u00e9 une licence avec <strong>Aquitaine Science Transfert<\/strong> pour industrialiser et commercialiser une technologie de rupture fond\u00e9e sur la culture cellulaire en 3D.<\/p>\n<p><a href=\"https:\/\/treefrog.fr\">treefrog.fr<\/a><\/p>\n<\/div>\n\t\t<\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>La premi\u00e8re promotion du French Tech 120 est enfin compl\u00e8te. 83 entreprises viennent rejoindre les 40 jeunes pousses du Next 40, dont\u00a06 start-up accompagn\u00e9es : Acticor Biotech, Dynacure, Inotrem, ImCheck Therapeutics, Keranova, Treefrog Therapeutics. Lanc\u00e9 en septembre 2019 par le Pr\u00e9sident de la R\u00e9publique et le Premier Ministre, le programme French Tech 120 illustre la [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":17753,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[562],"tags":[],"class_list":["post-17766","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-satt-network"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>French Tech 120 : 6 start-ups accompagn\u00e9es par les SATT parmi les entreprises s\u00e9lectionn\u00e9es - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/ft120\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/ft120\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/ft120\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\"},\"headline\":\"French Tech 120 : 6 start-ups accompagn\u00e9es par les SATT parmi les entreprises s\u00e9lectionn\u00e9es\",\"datePublished\":\"2020-01-31T13:21:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/ft120\/\"},\"wordCount\":868,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/ft120\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/FT120.jpg\",\"articleSection\":[\"SATT Network\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/ft120\/\",\"url\":\"https:\/\/www.satt.fr\/en\/ft120\/\",\"name\":\"French Tech 120 : 6 start-ups accompagn\u00e9es par les SATT parmi les entreprises s\u00e9lectionn\u00e9es - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/ft120\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/ft120\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/FT120.jpg\",\"datePublished\":\"2020-01-31T13:21:48+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/ft120\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/ft120\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/ft120\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/FT120.jpg\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/FT120.jpg\",\"width\":6399,\"height\":3569},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/ft120\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"French Tech 120 : 6 start-ups accompagn\u00e9es par les SATT parmi les entreprises s\u00e9lectionn\u00e9es\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\",\"name\":\"admin\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"French Tech 120 : 6 start-ups accompagn\u00e9es par les SATT parmi les entreprises s\u00e9lectionn\u00e9es - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/ft120\/","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/ft120\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/ft120\/"},"author":{"name":"admin","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec"},"headline":"French Tech 120 : 6 start-ups accompagn\u00e9es par les SATT parmi les entreprises s\u00e9lectionn\u00e9es","datePublished":"2020-01-31T13:21:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/ft120\/"},"wordCount":868,"image":{"@id":"https:\/\/www.satt.fr\/en\/ft120\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/FT120.jpg","articleSection":["SATT Network"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/ft120\/","url":"https:\/\/www.satt.fr\/en\/ft120\/","name":"French Tech 120 : 6 start-ups accompagn\u00e9es par les SATT parmi les entreprises s\u00e9lectionn\u00e9es - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/ft120\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/ft120\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/FT120.jpg","datePublished":"2020-01-31T13:21:48+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/ft120\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/ft120\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/ft120\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/FT120.jpg","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/FT120.jpg","width":6399,"height":3569},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/ft120\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"French Tech 120 : 6 start-ups accompagn\u00e9es par les SATT parmi les entreprises s\u00e9lectionn\u00e9es"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec","name":"admin","url":"https:\/\/www.satt.fr\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/17766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=17766"}],"version-history":[{"count":0,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/17766\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/17753"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=17766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=17766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=17766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}